299 related articles for article (PubMed ID: 15769894)
1. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
[TBL] [Abstract][Full Text] [Related]
2. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
4. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
6. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
10. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
11. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
12. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
Shimizu K; Asakura M; Fujii S
J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
14. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.
Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y
Mol Ther; 2008 Feb; 16(2):411-8. PubMed ID: 18059374
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.
Mailliard RB; Son YI; Redlinger R; Coates PT; Giermasz A; Morel PA; Storkus WJ; Kalinski P
J Immunol; 2003 Sep; 171(5):2366-73. PubMed ID: 12928383
[TBL] [Abstract][Full Text] [Related]
18. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
Balza E; Zanellato S; Poggi A; Reverberi D; Rubartelli A; Mortara L
Eur J Immunol; 2017 Apr; 47(4):743-753. PubMed ID: 28198545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]